湖北卖得理想的药品TOP100

2017-09-21 Sarah 医药观察家网

9月20日,湖北省基本药物集中采购平台发布了《全省基层医疗卫生机构2017年8月份药品网上集中采购情况》。

9月20日,湖北省基本药物集中采购平台发布了《全省基层医疗卫生机构2017年8月份药品网上集中采购情况》。

医药地方台在7315个药品中,筛选出采购额最多的100个药品,其中包括基本药物86个、补充药品7个、低价药品7个。

其中,采购额最多的三个药品分别是海南斯达制药有限公司的注射用炎琥宁,3239781.92元;其次是哈尔滨珍宝制药有限公司(原黑龙江省珍宝岛制药有限公司哈尔滨分公司)的注射用血塞通(冻干),3119948.8元;第三是浙江莎普爱思药业股份有限公司(原浙江莎普爱思制药有限公司)的乳酸左氧氟沙星氯化钠注射液,3113046.3元。

此外,在这100个药品中,产品最多的是华北制药河北华民药业有限责任公司,共4个,其次是四川科伦药业股份有限公司、宜昌人福药业有限责任公司、广西梧州制药(集团)股份有限公司各3个。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649838, encodeId=fd301649838e5, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Wed Jan 24 03:31:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256903, encodeId=e2bb25690398, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Oct 29 09:24:43 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248037, encodeId=91fd24803e08, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Wed Sep 27 06:15:36 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246333, encodeId=2a89246333ae, content=学习好.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Sep 21 13:30:18 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2018-01-24 respect
  2. [GetPortalCommentsPageByObjectIdResponse(id=1649838, encodeId=fd301649838e5, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Wed Jan 24 03:31:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256903, encodeId=e2bb25690398, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Oct 29 09:24:43 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248037, encodeId=91fd24803e08, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Wed Sep 27 06:15:36 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246333, encodeId=2a89246333ae, content=学习好.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Sep 21 13:30:18 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-10-29 周周人

    学习.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1649838, encodeId=fd301649838e5, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Wed Jan 24 03:31:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256903, encodeId=e2bb25690398, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Oct 29 09:24:43 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248037, encodeId=91fd24803e08, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Wed Sep 27 06:15:36 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246333, encodeId=2a89246333ae, content=学习好.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Sep 21 13:30:18 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-27 周周人

    学习.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1649838, encodeId=fd301649838e5, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Wed Jan 24 03:31:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256903, encodeId=e2bb25690398, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Oct 29 09:24:43 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248037, encodeId=91fd24803e08, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Wed Sep 27 06:15:36 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246333, encodeId=2a89246333ae, content=学习好.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Sep 21 13:30:18 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-21 惠映实验室

    学习好.谢谢.

    0

相关资讯

中国政策故事:“基本药物”变形记,一张推荐目录为何成医改抓手

在新医改最热闹的那几年,基本药物几乎是最热门的一个词汇。实际上,基本药物以及基本药物目录很早就在我国存在了,时间之早甚至超乎许多人的想象。 这个时间就是1979年,随着改革开放,我国重返国际社会,自然而然地重新参与到WHO的工作之中。基本药物概念最早是由WHO在1977年提出的,它是指满足大部分人口卫生保健需要的药物。 而为了应对全球卫生问题,当时的世卫组织制订了《基本药物标准清单》,